Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
AusPAR: Durvalumab
Australian Public Assessment Report
Device/Product Name
Imfinzi
Active ingredients
Durvalumab
AusPAR Date
Published
Sponsor
Submission Number
PM-2019-04661-1-4
Submission Type
Extension of indications
Decision
Approved